Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica
Alternative Names: CRA 0316; CRA 0450; CRA 1000; CRA 1001; CRA 1065; R 278995Latest Information Update: 18 Aug 2017
At a glance
- Originator Janssen Pharmaceutica; Taisho Pharmaceutical
- Class Antidepressants; Anxiolytics
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists; Corticotropin-releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 08 Aug 2017 Discontinued - Preclinical for Anxiety disorders in Japan (unspecified route)
- 08 Aug 2017 Discontinued - Preclinical for Major depressive disorder in Japan (unspecified route)
- 21 Oct 2009 Preclinical development in Anxiety disorders is ongoing in Japan